Group 1 - The core viewpoint of the article highlights the significant investment in AI-driven healthcare solutions, particularly in surgical robotics, as companies like Nvidia and Eli Lilly collaborate to establish a $1 billion AI drug discovery lab [1] - MicroPort Robotics-B (02252) has seen its stock price increase by over 7%, reaching HKD 28.2, with a trading volume of HKD 225 million, indicating strong market interest [1] - The company has reported a cumulative order of over 230 surgical robots, with more than 160 orders for endoscopic surgical robots, showcasing its growing market presence and demand [1] Group 2 - The approval of the bronchoscopic surgical robot "Dudao" by NMPA signifies a milestone for the company's product development and regulatory progress [1] - According to Zhongyou Securities, the surgical robot industry is entering a phase of commercialization and policy acceleration, which may benefit companies like MicroPort Robotics [1] - The company's globalization strategy is being validated in the market, with increasing competitiveness overseas and favorable domestic policies enhancing its market position [1]